<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Epilepsia Open</journal-id><journal-id journal-id-type="iso-abbrev">Epilepsia Open</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2470-9239</journal-id><journal-id journal-id-type="publisher-id">EPI4</journal-id><journal-title-group><journal-title>Epilepsia Open</journal-title></journal-title-group><issn pub-type="epub">2470-9239</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29588972</article-id><article-id pub-id-type="pmc">5862116</article-id><article-id pub-id-type="doi">10.1002/epi4.12079</article-id><article-id pub-id-type="publisher-id">EPI412079</article-id><article-categories><subj-group subj-group-type="overline"><subject>Full&#x02010;Length Original Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Full&#x02010;length Original Research</subject></subj-group></article-categories><title-group><article-title>Safety and tolerability of lacosamide monotherapy in the elderly: A subgroup analysis from lacosamide trials in diabetic neuropathic pain</article-title><alt-title alt-title-type="left-running-head">J. Bainbridge et&#x000a0;al.</alt-title></title-group><contrib-group><contrib id="epi412079-cr-0001" contrib-type="author"><name><surname>Bainbridge</surname><given-names>Jacquelyn</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5649-1564</contrib-id><xref ref-type="aff" rid="epi412079-aff-0001">
<sup>1</sup>
</xref><xref ref-type="bio" rid="epi412079-biog-0001">*</xref></contrib><contrib id="epi412079-cr-0002" contrib-type="author"><name><surname>De Backer</surname><given-names>Marc</given-names></name><xref ref-type="aff" rid="epi412079-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="epi412079-cr-0003" contrib-type="author"><name><surname>Eckhardt</surname><given-names>Klaus</given-names></name><xref ref-type="aff" rid="epi412079-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="epi412079-cr-0004" contrib-type="author"><name><surname>Tennigkeit</surname><given-names>Frank</given-names></name><xref ref-type="aff" rid="epi412079-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="epi412079-cr-0005" contrib-type="author"><name><surname>Bongardt</surname><given-names>Sabine</given-names></name><xref ref-type="aff" rid="epi412079-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="epi412079-cr-0006" contrib-type="author"><name><surname>Sen</surname><given-names>David</given-names></name><xref ref-type="aff" rid="epi412079-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="epi412079-cr-0007" contrib-type="author"><name><surname>Werhahn</surname><given-names>Konrad J.</given-names></name><xref ref-type="aff" rid="epi412079-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="epi412079-cr-0008" contrib-type="author"><name><surname>Shaibani</surname><given-names>Aziz</given-names></name><xref ref-type="aff" rid="epi412079-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="epi412079-cr-0009" contrib-type="author" corresp="yes"><name><surname>Faught</surname><given-names>Edward</given-names></name><address><email>rfaught@emory.edu</email></address><xref ref-type="aff" rid="epi412079-aff-0006">
<sup>6</sup>
</xref></contrib></contrib-group><aff id="epi412079-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">University of Colorado Anschutz Medical Campus</named-content>
<institution>Skaggs School of Pharmacy and Pharmaceutical Sciences</institution>
<named-content content-type="city">Aurora</named-content>
<named-content content-type="country-part">Colorado</named-content>
<country country="US">U.S.A</country>
</aff><aff id="epi412079-aff-0002">
<label><sup>2</sup></label>
<institution>UCB Pharma</institution>
<named-content content-type="city">Brussels</named-content>
<country country="BE">Belgium</country>
</aff><aff id="epi412079-aff-0003">
<label><sup>3</sup></label>
<institution>UCB Pharma</institution>
<named-content content-type="city">Monheim am Rhein</named-content>
<country country="DE">Germany</country>
</aff><aff id="epi412079-aff-0004">
<label><sup>4</sup></label>
<institution>UCB Pharma</institution>
<named-content content-type="city">Raleigh</named-content>
<named-content content-type="country-part">North Carolina</named-content>
<country country="US">U.S.A</country>
</aff><aff id="epi412079-aff-0005">
<label><sup>5</sup></label>
<institution>Nerve and Muscle Center of Texas</institution>
<named-content content-type="city">Houston</named-content>
<named-content content-type="country-part">Texas</named-content>
<country country="US">U.S.A</country>
</aff><aff id="epi412079-aff-0006">
<label><sup>6</sup></label>
<institution>Emory University School of Medicine</institution>
<named-content content-type="city">Atlanta</named-content>
<named-content content-type="country-part">Georgia</named-content>
<country country="US">U.S.A</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label>Address correspondence to Edward Faught, Emory University, Brain Health Center 292, 12 Executive Park Drive NE, Atlanta, GA 30329, U.S.A. E&#x02010;mail: <email>rfaught@emory.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>11</day><month>9</month><year>2017</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2017</year></pub-date><volume>2</volume><issue>4</issue><issue-id pub-id-type="doi">10.1002/epi4.2017.2.issue-4</issue-id><fpage>415</fpage><lpage>423</lpage><history><date date-type="accepted"><day>16</day><month>7</month><year>2017</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2017 International League Against Epilepsy <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2017 The Authors. <italic>Epilepsia Open</italic> published by Wiley Periodicals Inc. on behalf of International League Against Epilepsy.</copyright-statement><license license-type="creativeCommonsBy-nc-nd"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution&#x02010;NonCommercial&#x02010;NoDerivs</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x02010;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:EPI4-2-415.pdf"/><abstract id="epi412079-abs-0001"><title>Summary</title><sec id="epi412079-sec-0001"><title>Objective</title><p>To assess the safety profile of lacosamide monotherapy in elderly (&#x02265;65&#x000a0;years) subjects with diabetic neuropathic pain (<styled-content style="fixed-case">DNP</styled-content>).</p></sec><sec id="epi412079-sec-0002"><title>Methods</title><p>Of 1,863 <styled-content style="fixed-case">DNP</styled-content> subjects in double&#x02010;blind, randomized, placebo&#x02010;controlled trials of lacosamide monotherapy (NCT00861445, NCT00235469, NCT00238524, NCT00135109, NCT00350103), 502 were elderly. Safety data from elderly subjects were compared with that of younger subjects (&#x0003c;65&#x000a0;years) within these <styled-content style="fixed-case">DNP</styled-content> trials. It should be noted that lacosamide is approved for the treatment of focal (partial&#x02010;onset) seizures; it is not approved/recommended for the treatment of <styled-content style="fixed-case">DNP</styled-content>.</p></sec><sec id="epi412079-sec-0003"><title>Results</title><p>Overall, cardiovascular diseases were prevalent in the <styled-content style="fixed-case">DNP</styled-content> population, as was the use of cardiac, blood pressure, diabetes, and cholesterol&#x02010;lowering medications among both young and elderly subjects. The most frequently reported adverse events (<styled-content style="fixed-case">AE</styled-content>s) for lacosamide monotherapy (200, 400, and 600&#x000a0;mg/day combined) in elderly versus younger subjects were dizziness (16.2% vs. 13.2%), nausea (10.0% vs. 9.4%), and headache (8.0% vs. 8.7%). Incidences of cardiac disorder <styled-content style="fixed-case">AE</styled-content>s were higher in elderly versus younger subjects receiving placebo (6.2% vs. 3.9%), lacosamide 200 (4.8% vs. 3.3%), lacosamide 400 (7.0% vs. 4.1%), and lacosamide 600&#x000a0;mg/day (7.7% vs. 4.0%). Discontinuation rates because of any <styled-content style="fixed-case">AE</styled-content> in the elderly versus younger subjects were similar for placebo (8.8% vs. 7.0%) and lacosamide 200&#x000a0;mg/day (9.6% vs. 11.9%) and higher for lacosamide 400 (25.1% vs. 10.8%) and lacosamide 600&#x000a0;mg/day (52.7% vs. 28.3%).</p></sec><sec id="epi412079-sec-0004"><title>Significance</title><p>Lacosamide monotherapy was well tolerated in elderly subjects with <styled-content style="fixed-case">DNP</styled-content>, with an overall <styled-content style="fixed-case">AE</styled-content> profile consistent with that reported in epilepsy trials.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="epi412079-kwd-0001">Lacosamide</kwd><kwd id="epi412079-kwd-0002">Elderly</kwd><kwd id="epi412079-kwd-0003">Epilepsy</kwd><kwd id="epi412079-kwd-0004">Tolerability</kwd><kwd id="epi412079-kwd-0005">Safety</kwd></kwd-group><funding-group><award-group><funding-source>UCB Pharma</funding-source></award-group><award-group><funding-source>Supernus</funding-source></award-group><award-group><funding-source>NINDS</funding-source></award-group></funding-group><counts><fig-count count="0"/><table-count count="6"/><page-count count="9"/><word-count count="7208"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>epi412079</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>December 2017</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.3.3 mode:remove_FC converted:21.03.2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>
<boxed-text position="anchor" content-type="box" id="epi412079-blkfxd-0001" orientation="portrait"><caption><title>Key Points</title></caption><p>
<list list-type="bullet" id="epi412079-list-0001"><list-item><p>Compared with epilepsy trials, diabetic neuropathic pain trials enrolled higher numbers of elderly, allowing insight into lacosamide safety in the elderly</p></list-item><list-item><p>Lacosamide monotherapy was well tolerated in the diabetic neuropathic pain population</p></list-item><list-item><p>Discontinuation rates due to adverse events at a lacosamide dose of 200&#x000a0;mg/day were similar between the elderly and younger diabetic neuropathic pain populations</p></list-item><list-item><p>The higher discontinuation rate of the elderly vs. younger group on 400&#x02013;600&#x000a0;mg/day lacosamide supports tailoring dose based on subject response and tolerability</p></list-item><list-item><p>The choice of an antiepileptic drug in the elderly should be guided by the drug's efficacy, metabolism, pharmacokinetics, and tolerability profile</p></list-item></list>
</p></boxed-text>
</p><sec id="epi412079-sec-0006"><p>The elderly population is the fastest growing segment of the global population in many developed countries. New&#x02010;onset epilepsy incidence is increasing with age mainly owing to cerebrovascular disease.<xref rid="epi412079-bib-0001" ref-type="ref">1</xref>, <xref rid="epi412079-bib-0002" ref-type="ref">2</xref>, <xref rid="epi412079-bib-0003" ref-type="ref">3</xref> In one study using U.S. Medicare beneficiaries 65 years of age and older, the average annual prevalence and incidence rates for epilepsy were 10.8 and 2.4 per 1,000, respectively.<xref rid="epi412079-bib-0004" ref-type="ref">4</xref> The rates were higher for some minorities and increased with age for all gender and race segments.<xref rid="epi412079-bib-0004" ref-type="ref">4</xref> By the year 2020, approximately half of the newly diagnosed subjects with seizures will be 60&#x000a0;years of age and older.<xref rid="epi412079-bib-0005" ref-type="ref">5</xref>
</p><p>Given that elderly subjects with epilepsy are usually treated with antiepileptic drugs (AEDs) in monotherapy, data on the tolerability of lacosamide as monotherapy in the elderly are informative for clinical practice.<xref rid="epi412079-bib-0003" ref-type="ref">3</xref>, <xref rid="epi412079-bib-0006" ref-type="ref">6</xref> As people age, they experience more concomitant disease states that typically correlate with an increase in the number of medications taken and increased likelihood of drug&#x02010;drug interactions.<xref rid="epi412079-bib-0007" ref-type="ref">7</xref> Furthermore, older subjects are more susceptible to drugs&#x02019; adverse effects because aging is associated with metabolic changes that reduce drug clearance and increase pharmacodynamic sensitivity, thereby decreasing the therapeutic window of a given drug.<xref rid="epi412079-bib-0008" ref-type="ref">8</xref> Therefore, the ideal AED for the elderly should be well tolerated and have a low potential for drug&#x02010;drug interactions.</p><p>Lacosamide is currently approved for monotherapy (United States up to 400&#x000a0;mg/day; European Union up to 600&#x000a0;mg/day) or adjunctive treatment (United States, European Union, and other countries up to 400&#x000a0;mg/day) of focal epilepsy in adults.<xref rid="epi412079-bib-0009" ref-type="ref">9</xref>, <xref rid="epi412079-bib-0010" ref-type="ref">10</xref> Lacosamide has a favorable pharmacokinetic profile with low potential for clinically relevant drug&#x02010;drug interactions.<xref rid="epi412079-bib-0011" ref-type="ref">11</xref> The safety and tolerability of lacosamide were reported in a pooled analysis of pivotal adjunctive clinical trials of generally healthy subjects with focal epilepsy.<xref rid="epi412079-bib-0012" ref-type="ref">12</xref> The most common treatment&#x02010;emergent adverse events (AEs) associated with lacosamide (up to 600&#x000a0;mg/day) were dizziness (30.6% vs. 8.2% placebo), headache (12.7% vs. 8.8% placebo), nausea (11.4% vs. 4.4% placebo), and diplopia (10.5% vs. 1.9% placebo); except for headache, these AEs appeared to be related to dose.<xref rid="epi412079-bib-0012" ref-type="ref">12</xref> The only AEs leading to at least 5% of subjects in any dose group discontinuing were dizziness and ataxia. The cardiac safety of AEDs affecting voltage&#x02010;gated sodium channels is of interest, and a study of pooled adjunctive lacosamide safety data has recently been reported.<xref rid="epi412079-bib-0013" ref-type="ref">13</xref> At doses up to 400&#x000a0;mg/day in adjunctive use, lacosamide did not prolong QTc interval or affect heart rate or QRS duration; however, a slight increase in PR interval was observed.<xref rid="epi412079-bib-0013" ref-type="ref">13</xref> This finding may be more relevant for an elderly population.</p><p>The number of elderly subjects (&#x02265;65&#x000a0;years) enrolled in the pivotal focal epilepsy trials with adjunctive lacosamide<xref rid="epi412079-bib-0014" ref-type="ref">14</xref>, <xref rid="epi412079-bib-0015" ref-type="ref">15</xref>, <xref rid="epi412079-bib-0016" ref-type="ref">16</xref> was limited (n&#x000a0;=&#x000a0;18, 1.4%; data on file, UCB Pharma), and there are limited data available in elderly subjects receiving lacosamide in monotherapy for focal epilepsy.<xref rid="epi412079-bib-0017" ref-type="ref">17</xref> However, a large proportion (n&#x000a0;=&#x000a0;502, 26.9%) of elderly subjects was enrolled in the lacosamide monotherapy trials for diabetic neuropathic pain (DNP; discontinued development program), which provides an opportunity to increase the number of elderly subjects that can be evaluated for lacosamide safety and tolerability within the dosing range of 200&#x02013;600&#x000a0;mg/day.<xref rid="epi412079-bib-0018" ref-type="ref">18</xref>, <xref rid="epi412079-bib-0019" ref-type="ref">19</xref>, <xref rid="epi412079-bib-0020" ref-type="ref">20</xref>, <xref rid="epi412079-bib-0021" ref-type="ref">21</xref>, <xref rid="epi412079-bib-0022" ref-type="ref">22</xref> It should be noted that the U.S. Food and Drug Administration (FDA) stated that lacosamide was not approvable for the treatment of DNP. UCB Pharma does not recommend the use of its products in a manner other than as indicated in the prescribing information or summary of product characteristics. However, because data on the tolerability of lacosamide in the elderly would be informative for clinical practice, a post hoc analysis of pooled safety and tolerability data of lacosamide in monotherapy in the elderly subgroup from the randomized, double&#x02010;blinded, and placebo&#x02010;controlled DNP studies was undertaken.</p></sec><sec id="epi412079-sec-0007"><title>Methods</title><sec id="epi412079-sec-0008"><title>Study design</title><p>Five lacosamide monotherapy DNP trials (NCT00861445, NCT00235469, NCT00238524, NCT00135109, NCT00350103) had similar placebo&#x02010;controlled, double&#x02010;blind trial designs, had comparable duration of treatment (titration and maintenance phases), and used similar randomized dosing (200, 400, and 600&#x000a0;mg/day) (Table&#x000a0;<xref rid="epi412079-tbl-0001" ref-type="table-wrap">1</xref>). All studies were phase 2 through phase 3b studies. Within lacosamide dosing of 200&#x02013;600&#x000a0;mg/day, safety data of the elderly subgroup pooled from the dose&#x02010;randomized DNP trials were compared with those of the younger subjects (&#x0003c;65&#x000a0;years) pooled from the same DNP trials.</p><table-wrap id="epi412079-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Pooled clinical trials of lacosamide monotherapy for diabetic neuropathic pain</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Study ID</th><th align="center" valign="top" rowspan="1" colspan="1">Phase</th><th align="center" valign="top" rowspan="1" colspan="1">Design</th><th align="center" valign="top" rowspan="1" colspan="1">Duration (weeks) Baseline/titration<xref ref-type="fn" rid="epi412079-note-0002">a</xref>/maintenance</th><th align="center" valign="top" rowspan="1" colspan="1">Randomization</th><th align="center" valign="top" rowspan="1" colspan="1">Dose groups<xref ref-type="fn" rid="epi412079-note-0003">b</xref>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">SP614<xref rid="epi412079-bib-0018" ref-type="ref">18</xref> NCT00861445</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">Double&#x02010;blind</td><td align="center" rowspan="1" colspan="1">1/6<xref ref-type="fn" rid="epi412079-note-0002">a</xref>/4</td><td align="center" rowspan="1" colspan="1">1:1</td><td align="center" rowspan="1" colspan="1">Placebo or lacosamide 400&#x000a0;mg/day</td></tr><tr><td align="left" rowspan="1" colspan="1">SP742<xref rid="epi412079-bib-0019" ref-type="ref">19</xref> NCT00235469</td><td align="center" rowspan="1" colspan="1">2b</td><td align="center" rowspan="1" colspan="1">Double&#x02010;blind</td><td align="center" rowspan="1" colspan="1">2/6/12</td><td align="center" rowspan="1" colspan="1">1:1:1:1</td><td align="center" rowspan="1" colspan="1">Placebo, lacosamide 200, 400, or 600&#x000a0;mg/day</td></tr><tr><td align="left" rowspan="1" colspan="1">SP743<xref rid="epi412079-bib-0020" ref-type="ref">20</xref> NCT00238524</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">Double&#x02010;blind</td><td align="center" rowspan="1" colspan="1">2/6/12</td><td align="center" rowspan="1" colspan="1">1:2:2</td><td align="center" rowspan="1" colspan="1">Placebo, lacosamide 400 or 600&#x000a0;mg/day<xref ref-type="fn" rid="epi412079-note-0004">c</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">SP768<xref rid="epi412079-bib-0021" ref-type="ref">21</xref> NCT00135109</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">Double&#x02010;blind</td><td align="center" rowspan="1" colspan="1">2/6/12</td><td align="center" rowspan="1" colspan="1">1:2:2:2</td><td align="center" rowspan="1" colspan="1">Placebo, lacosamide 200, 400, or 600&#x000a0;mg/day</td></tr><tr><td align="left" rowspan="1" colspan="1">SP874<xref rid="epi412079-bib-0022" ref-type="ref">22</xref> NCT00350103</td><td align="center" rowspan="1" colspan="1">3b</td><td align="center" rowspan="1" colspan="1">Double&#x02010;blind</td><td align="center" rowspan="1" colspan="1">2/4<xref ref-type="fn" rid="epi412079-note-0005">d</xref>/12</td><td align="center" rowspan="1" colspan="1">1:1:1</td><td align="center" rowspan="1" colspan="1">Placebo, lacosamide 400&#x000a0;mg/day ST or FT<xref ref-type="fn" rid="epi412079-note-0005">d</xref>
</td></tr></tbody></table><table-wrap-foot><fn id="epi412079-note-0001"><p>FT, fast titration; ST, standard titration.</p></fn><fn id="epi412079-note-0002"><label>a</label><p>ST with dose increased to the randomized dose in 100&#x02010;mg/day weekly increments (beginning with 50&#x000a0;mg twice daily), except for SP614, which started at 100&#x000a0;mg/day for 3&#x000a0;weeks, then titrated by 100&#x000a0;mg/day every week over the next 3&#x000a0;weeks.</p></fn><fn id="epi412079-note-0003"><label>b</label><p>No down&#x02010;titration was allowed owing to an intolerable adverse event, except for SP614.</p></fn><fn fn-type="equal" id="epi412079-note-0004"><label>c</label><p>Subjects in the 400&#x02010;mg/day group were further randomized equally to either a slow (100&#x000a0;mg/day for 3&#x000a0;weeks, followed by weekly increases of 100 to 400&#x000a0;mg/day at week 6) or ST scheme.</p></fn><fn id="epi412079-note-0005"><label>d</label><p>SP874 FT: started at 200&#x000a0;mg/day for 3&#x000a0;days, increased to 300&#x000a0;mg/day during the next 4&#x000a0;days, and 400&#x000a0;mg/day after 1&#x000a0;week.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap></sec><sec id="epi412079-sec-0009"><title>Subject eligibility</title><p>Subject eligibility in the DNP trials included &#x02265;18&#x000a0;years of age with symptoms of painful distal diabetic neuropathy for 6&#x000a0;months to 5&#x000a0;years (1&#x02013;5&#x000a0;years in SP614), a diagnosis of diabetes mellitus (type 1 or type 2), and at least moderate pain defined as an average pain intensity of &#x02265;4 on an 11&#x02010;point Likert scale (0&#x02013;10) during the 7&#x000a0;days before randomization.</p></sec><sec id="epi412079-sec-0010"><title>Statistical analysis</title><p>Data from all treated subjects from the double&#x02010;blind, placebo&#x02010;controlled trials for DNP were pooled. Descriptive statistics were used to compare subject disposition, demographics, and AEs. Comparisons were made within the DNP population between placebo and lacosamide doses and between age categories (&#x02265;65 and &#x0003c;65&#x000a0;years). In post hoc analyses, the relationship between the incidence of AEs and treatment along with a set of covariates was investigated using a negative binomial regression model. In addition, the relationship between AEs leading to discontinuation and treatment along with a set of covariates was explored. A Cox proportional hazards model was used to analyze the time to discontinuation due to AEs and included treatment and a set of covariates. Owing to a statistically significant interaction between treatment and age, the final analysis was performed for each lacosamide dose group (200, 400, and 600&#x000a0;mg/day) using a Cox proportional hazards model to investigate the relationship between discontinuation due to AEs and a set of covariates. The covariates included age (&#x02265;65 vs. &#x0003c;65&#x000a0;years), sex, number of concomitant medications, number of concomitant diseases, years with diabetic neuropathy, and treatment duration (only included in the negative binomial regression model).</p></sec></sec><sec id="epi412079-sec-0011"><title>Results</title><sec id="epi412079-sec-0012"><title>Subject disposition</title><p>A total of 1,863 subjects were enrolled in the double&#x02010;blind, placebo&#x02010;controlled DNP trials and were evaluated at either placebo or the lacosamide 200&#x02010;, 400&#x02010;, or 600&#x02010;mg/day dose. Of these, 1,361 were young (&#x0003c;65&#x000a0;years) and 502 were elderly (&#x02265;65&#x000a0;years) (Table&#x000a0;<xref rid="epi412079-tbl-0002" ref-type="table-wrap">2</xref>).</p><table-wrap id="epi412079-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Subject enrollment in the pooled clinical trials of lacosamide monotherapy for diabetic neuropathic pain, presented by age (&#x0003c;65&#x000a0;years or &#x02265;65&#x000a0;years)</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" valign="top" colspan="1"/><th align="center" colspan="5" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Study ID</th><th align="center" rowspan="2" valign="top" colspan="1">Pooled</th></tr><tr style="border-bottom:solid 1px #000000"><th align="center" valign="top" rowspan="1" colspan="1">SP614</th><th align="center" valign="top" rowspan="1" colspan="1">SP742</th><th align="center" valign="top" rowspan="1" colspan="1">SP743</th><th align="center" valign="top" rowspan="1" colspan="1">SP768</th><th align="center" valign="top" rowspan="1" colspan="1">SP874</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Total (SS)</td><td align="char" char="." rowspan="1" colspan="1">119</td><td align="char" char="." rowspan="1" colspan="1">370</td><td align="char" char="." rowspan="1" colspan="1">357</td><td align="char" char="." rowspan="1" colspan="1">468</td><td align="char" char="." rowspan="1" colspan="1">549</td><td align="char" char=" " rowspan="1" colspan="1">1,863</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x02265;65&#x000a0;years</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" char=" " rowspan="1" colspan="1">502 (26.9%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x0003c;65&#x000a0;years</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" char=" " rowspan="1" colspan="1">1,361 (73.1%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Placebo</td><td align="char" char="." rowspan="1" colspan="1">59</td><td align="char" char="." rowspan="1" colspan="1">93</td><td align="char" char="." rowspan="1" colspan="1">74</td><td align="char" char="." rowspan="1" colspan="1">65</td><td align="char" char="." rowspan="1" colspan="1">179</td><td align="char" char=" " rowspan="1" colspan="1">470</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x02265;65&#x000a0;years</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" char=" " rowspan="1" colspan="1">113 (24.0%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x0003c;65&#x000a0;years</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" char=" " rowspan="1" colspan="1">357 (76.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Lacosamide 200&#x000a0;mg/day</td><td align="char" char="." rowspan="1" colspan="1">n/a</td><td align="char" char="." rowspan="1" colspan="1">93</td><td align="char" char="." rowspan="1" colspan="1">n/a</td><td align="char" char="." rowspan="1" colspan="1">141</td><td align="char" char="." rowspan="1" colspan="1">n/a</td><td align="char" char=" " rowspan="1" colspan="1">234</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x02265;65&#x000a0;years</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" char=" " rowspan="1" colspan="1">83 (35.5%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x0003c;65&#x000a0;years</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" char=" " rowspan="1" colspan="1">151 (64.5%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Lacosamide 400&#x000a0;mg/day</td><td align="char" char="." rowspan="1" colspan="1">60</td><td align="char" char="." rowspan="1" colspan="1">91</td><td align="char" char="." rowspan="1" colspan="1">150</td><td align="char" char="." rowspan="1" colspan="1">125</td><td align="char" char="." rowspan="1" colspan="1">370</td><td align="char" char=" " rowspan="1" colspan="1">796</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x02265;65&#x000a0;years</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" char=" " rowspan="1" colspan="1">215 (27.0%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x0003c;65&#x000a0;years</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" char=" " rowspan="1" colspan="1">581 (73.0%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Lacosamide 600&#x000a0;mg/day</td><td align="char" char="." rowspan="1" colspan="1">n/a</td><td align="char" char="." rowspan="1" colspan="1">93</td><td align="char" char="." rowspan="1" colspan="1">133</td><td align="char" char="." rowspan="1" colspan="1">137</td><td align="char" char="." rowspan="1" colspan="1">n/a</td><td align="char" char=" " rowspan="1" colspan="1">363</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x02265;65&#x000a0;years</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" char=" " rowspan="1" colspan="1">91 (25.1%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x0003c;65&#x000a0;years</td><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" rowspan="1" colspan="1"/><td align="char" char=" " rowspan="1" colspan="1">272 (74.9%)</td></tr></tbody></table><table-wrap-foot><fn id="epi412079-note-0006"><p>n/a, not applicable; SS, safety set.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap></sec><sec id="epi412079-sec-0013"><title>Subject demographics and characteristics</title><p>Overall, cardiovascular diseases and use of cardiac, blood pressure, diabetes, and cholesterol&#x02010;lowering medications were prevalent, owing to subjects' older age and underlying diabetes (Table&#x000a0;<xref rid="epi412079-tbl-0003" ref-type="table-wrap">3</xref>). The most concomitant disease states (apart from the underlying diseases of DNP and diabetes) reported as &#x02265;5% of the population were hypertension (68.9%), hyperlipidemia (21.0%), hypercholesterolemia (20.6%), osteoarthritis (14.9%), and obesity (14.7%). Preexisting cardiac disease occurring in &#x02265;5% of a treatment arm was reported for coronary artery disease (placebo, 6.0%; 200, 400, and 600&#x000a0;mg/day lacosamide, 9.8%, 5.5%, 9.6%, respectively [7.0% overall]) and myocardial ischemia (placebo, 4.5%; 200, 400, and 600&#x000a0;mg/day lacosamide, 0%, 5.7%, 4.1%, respectively [4.3% overall]). The elderly subjects tended to have higher frequencies of concomitant diseases and medications compared with the younger subjects (Table&#x000a0;<xref rid="epi412079-tbl-0003" ref-type="table-wrap">3</xref>).</p><table-wrap id="epi412079-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label><caption><p>Subject demographics and characteristics in the pooled clinical trials of lacosamide monotherapy for diabetic neuropathic pain</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">Total N&#x000a0;=&#x000a0;1,863</th><th align="center" valign="top" rowspan="1" colspan="1">&#x0003c;65&#x000a0;years N&#x000a0;=&#x000a0;1,361</th><th align="center" valign="top" rowspan="1" colspan="1">&#x02265;65&#x000a0;years N&#x000a0;=&#x000a0;502</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, mean (SD), years</td><td align="char" char="." rowspan="1" colspan="1">58.1 (10.02)</td><td align="char" char="." rowspan="1" colspan="1">53.8 (7.85)</td><td align="char" char="." rowspan="1" colspan="1">69.9 (4.01)</td></tr><tr><td align="left" rowspan="1" colspan="1">Male/female, %</td><td align="char" char="." rowspan="1" colspan="1">52.9/47.1</td><td align="char" char="." rowspan="1" colspan="1">53.0/47.0</td><td align="char" char="." rowspan="1" colspan="1">52.6/47.4</td></tr><tr><td align="left" colspan="4" rowspan="1">Concomitant diseases &#x02265;5% in total population, %</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diabetic neuropathy</td><td align="char" char="." rowspan="1" colspan="1">99.8</td><td align="char" char="." rowspan="1" colspan="1">99.9</td><td align="char" char="." rowspan="1" colspan="1">99.8</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diabetes mellitus&#x02014;non&#x02013;insulin&#x02010;dependent</td><td align="char" char="." rowspan="1" colspan="1">83.5</td><td align="char" char="." rowspan="1" colspan="1">79.9</td><td align="char" char="." rowspan="1" colspan="1">93.0</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hypertension</td><td align="char" char="." rowspan="1" colspan="1">68.9</td><td align="char" char="." rowspan="1" colspan="1">64.6</td><td align="char" char="." rowspan="1" colspan="1">80.7</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hyperlipidemia</td><td align="char" char="." rowspan="1" colspan="1">21.0</td><td align="char" char="." rowspan="1" colspan="1">19.9</td><td align="char" char="." rowspan="1" colspan="1">23.9</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hypercholesterolemia</td><td align="char" char="." rowspan="1" colspan="1">20.6</td><td align="char" char="." rowspan="1" colspan="1">18.8</td><td align="char" char="." rowspan="1" colspan="1">25.3</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Osteoarthritis</td><td align="char" char="." rowspan="1" colspan="1">14.9</td><td align="char" char="." rowspan="1" colspan="1">12.7</td><td align="char" char="." rowspan="1" colspan="1">20.7</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Obesity</td><td align="char" char="." rowspan="1" colspan="1">14.7</td><td align="char" char="." rowspan="1" colspan="1">14.3</td><td align="char" char="." rowspan="1" colspan="1">15.7</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diabetic retinopathy</td><td align="char" char="." rowspan="1" colspan="1">11.8</td><td align="char" char="." rowspan="1" colspan="1">13.5</td><td align="char" char="." rowspan="1" colspan="1">7.2</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Gastroesophageal reflux disease</td><td align="char" char="." rowspan="1" colspan="1">11.1</td><td align="char" char="." rowspan="1" colspan="1">9.5</td><td align="char" char="." rowspan="1" colspan="1">15.5</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Depression</td><td align="char" char="." rowspan="1" colspan="1">10.5</td><td align="char" char="." rowspan="1" colspan="1">11.4</td><td align="char" char="." rowspan="1" colspan="1">8.0</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Drug hypersensitivity</td><td align="char" char="." rowspan="1" colspan="1">10.4</td><td align="char" char="." rowspan="1" colspan="1">9.3</td><td align="char" char="." rowspan="1" colspan="1">13.1</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diabetes mellitus&#x02014;insulin&#x02010;dependent</td><td align="char" char="." rowspan="1" colspan="1">10.1</td><td align="char" char="." rowspan="1" colspan="1">12.9</td><td align="char" char="." rowspan="1" colspan="1">2.6</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Insomnia</td><td align="char" char="." rowspan="1" colspan="1">7.8</td><td align="char" char="." rowspan="1" colspan="1">7.9</td><td align="char" char="." rowspan="1" colspan="1">7.8</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Hypothyroidism</td><td align="char" char="." rowspan="1" colspan="1">7.6</td><td align="char" char="." rowspan="1" colspan="1">6.7</td><td align="char" char="." rowspan="1" colspan="1">10.2</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Seasonal allergy</td><td align="char" char="." rowspan="1" colspan="1">7.1</td><td align="char" char="." rowspan="1" colspan="1">7.0</td><td align="char" char="." rowspan="1" colspan="1">7.6</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Coronary artery disease</td><td align="char" char="." rowspan="1" colspan="1">7.0</td><td align="char" char="." rowspan="1" colspan="1">5.7</td><td align="char" char="." rowspan="1" colspan="1">10.6</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Back pain</td><td align="char" char="." rowspan="1" colspan="1">6.9</td><td align="char" char="." rowspan="1" colspan="1">6.0</td><td align="char" char="." rowspan="1" colspan="1">9.4</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Arthritis</td><td align="char" char="." rowspan="1" colspan="1">6.0</td><td align="char" char="." rowspan="1" colspan="1">4.9</td><td align="char" char="." rowspan="1" colspan="1">9.0</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Erectile dysfunction</td><td align="char" char="." rowspan="1" colspan="1">6.0</td><td align="char" char="." rowspan="1" colspan="1">5.1</td><td align="char" char="." rowspan="1" colspan="1">8.6</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Asthma</td><td align="char" char="." rowspan="1" colspan="1">5.8</td><td align="char" char="." rowspan="1" colspan="1">6.5</td><td align="char" char="." rowspan="1" colspan="1">3.8</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Edema peripheral</td><td align="char" char="." rowspan="1" colspan="1">5.1</td><td align="char" char="." rowspan="1" colspan="1">3.9</td><td align="char" char="." rowspan="1" colspan="1">8.4</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Cataract</td><td align="char" char="." rowspan="1" colspan="1">5.0</td><td align="char" char="." rowspan="1" colspan="1">3.2</td><td align="char" char="." rowspan="1" colspan="1">9.8</td></tr><tr><td align="left" colspan="4" rowspan="1">Concomitant medications taken by &#x02265;10% in total population, %</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Antidiabetics&#x02014;biguanides</td><td align="char" char="." rowspan="1" colspan="1">49.9</td><td align="char" char="." rowspan="1" colspan="1">49.3</td><td align="char" char="." rowspan="1" colspan="1">51.6</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">ACE inhibitors</td><td align="char" char="." rowspan="1" colspan="1">44.0</td><td align="char" char="." rowspan="1" colspan="1">44.7</td><td align="char" char="." rowspan="1" colspan="1">42.0</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Lipid&#x02010;lowering agent&#x02014;statins</td><td align="char" char="." rowspan="1" colspan="1">39.5</td><td align="char" char="." rowspan="1" colspan="1">36.9</td><td align="char" char="." rowspan="1" colspan="1">46.6</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Analgesics</td><td align="char" char="." rowspan="1" colspan="1">38.4</td><td align="char" char="." rowspan="1" colspan="1">38.3</td><td align="char" char="." rowspan="1" colspan="1">38.8</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Antithrombotic agents</td><td align="char" char="." rowspan="1" colspan="1">37.8</td><td align="char" char="." rowspan="1" colspan="1">33.0</td><td align="char" char="." rowspan="1" colspan="1">51.0</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Antidiabetics&#x02014;sulfonamides</td><td align="char" char="." rowspan="1" colspan="1">33.9</td><td align="char" char="." rowspan="1" colspan="1">31.7</td><td align="char" char="." rowspan="1" colspan="1">39.8</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Antidiabetics&#x02014;insulins fast&#x02010;acting</td><td align="char" char="." rowspan="1" colspan="1">32.6</td><td align="char" char="." rowspan="1" colspan="1">35.9</td><td align="char" char="." rowspan="1" colspan="1">23.9</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Beta&#x02010;blocking agents</td><td align="char" char="." rowspan="1" colspan="1">24.6</td><td align="char" char="." rowspan="1" colspan="1">23.1</td><td align="char" char="." rowspan="1" colspan="1">28.5</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Antidiabetics&#x02014;insulins intermediate&#x02010;acting</td><td align="char" char="." rowspan="1" colspan="1">17.5</td><td align="char" char="." rowspan="1" colspan="1">18.8</td><td align="char" char="." rowspan="1" colspan="1">13.9</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Calcium channel blockers</td><td align="char" char="." rowspan="1" colspan="1">14.3</td><td align="char" char="." rowspan="1" colspan="1">12.4</td><td align="char" char="." rowspan="1" colspan="1">19.5</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Antidiabetics&#x02014;insulins long&#x02010;acting</td><td align="char" char="." rowspan="1" colspan="1">14.2</td><td align="char" char="." rowspan="1" colspan="1">15.0</td><td align="char" char="." rowspan="1" colspan="1">12.2</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Antidiabetics&#x02014;thiazolidinediones</td><td align="char" char="." rowspan="1" colspan="1">14.0</td><td align="char" char="." rowspan="1" colspan="1">14.3</td><td align="char" char="." rowspan="1" colspan="1">13.1</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Proton pump inhibitors</td><td align="char" char="." rowspan="1" colspan="1">12.7</td><td align="char" char="." rowspan="1" colspan="1">11.7</td><td align="char" char="." rowspan="1" colspan="1">15.5</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Angiotensin II antagonists</td><td align="char" char="." rowspan="1" colspan="1">12.2</td><td align="char" char="." rowspan="1" colspan="1">10.7</td><td align="char" char="." rowspan="1" colspan="1">16.5</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Diuretics&#x02014;sulfonamides</td><td align="char" char="." rowspan="1" colspan="1">10.3</td><td align="char" char="." rowspan="1" colspan="1">9.0</td><td align="char" char="." rowspan="1" colspan="1">13.5</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Multivitamins</td><td align="char" char="." rowspan="1" colspan="1">10.3</td><td align="char" char="." rowspan="1" colspan="1">9.3</td><td align="char" char="." rowspan="1" colspan="1">12.7</td></tr></tbody></table><table-wrap-foot><fn id="epi412079-note-0007"><p>ACE, angiotensin&#x02010;converting enzyme; SD, standard deviation.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap></sec><sec id="epi412079-sec-0014"><title>Adverse events during the treatment phase</title><p>Dose&#x02010;response relationships for AEs were analyzed by comparing the incidence of AEs in the lacosamide 200&#x02010;, 400&#x02010;, and 600&#x02010;mg/day groups versus placebo. The most frequently reported AEs for lacosamide monotherapy (all doses combined) in elderly versus younger subjects were dizziness (16.2% vs. 13.2%), nausea (10.0% vs. 9.4%), and headache (8.0% vs. 8.7%). The incidences of cardiac disorder AEs were higher in elderly versus younger subjects in placebo (6.2% vs. 3.9%), lacosamide 200&#x000a0;mg/day (4.8% vs. 3.3%), lacosamide 400&#x000a0;mg/day (7.0% vs. 4.1%), and lacosamide 600&#x000a0;mg/day (7.7% vs. 4.0%) groups, but there was no difference between the lacosamide and corresponding placebo groups within each age category (Table&#x000a0;<xref rid="epi412079-tbl-0004" ref-type="table-wrap">4</xref>). The incidences of specific cardiac AEs are shown in Table&#x000a0;<xref rid="epi412079-sup-0001" ref-type="supplementary-material">S1</xref>. Among other AEs particularly relevant to the elderly, the frequencies of tremor and balance disorder were higher in elderly versus younger subjects and dose&#x02010;related. Frequencies of fall and gait disturbance were low and similar between elderly and younger subjects (Table&#x000a0;<xref rid="epi412079-tbl-0004" ref-type="table-wrap">4</xref>). The incidence of serious AEs was similar between elderly and younger subjects, and the incidence of serious cardiac AEs was low (Table&#x000a0;<xref rid="epi412079-tbl-0004" ref-type="table-wrap">4</xref>).</p><table-wrap id="epi412079-tbl-0004" xml:lang="en" orientation="portrait" position="float"><label>Table 4</label><caption><p>AEs and SAEs recorded during the treatment phase (i.e., titration and maintenance phase) with lacosamide monotherapy in subjects with diabetic neuropathic pain, presented by age (&#x0003c;65&#x000a0;years or &#x02265;65&#x000a0;years)</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">Placebo &#x02265;65&#x000a0;years (n&#x000a0;=&#x000a0;113) &#x0003c;65&#x000a0;years (n&#x000a0;=&#x000a0;357)</th><th align="center" valign="top" rowspan="1" colspan="1">Lacosamide 200&#x000a0;mg/day &#x02265;65&#x000a0;years (n&#x000a0;=&#x000a0;83) &#x0003c;65&#x000a0;years (n&#x000a0;=&#x000a0;151)</th><th align="center" valign="top" rowspan="1" colspan="1">Lacosamide 400&#x000a0;mg/day &#x02265;65&#x000a0;years (n&#x000a0;=&#x000a0;215) &#x0003c;65&#x000a0;years (n&#x000a0;=&#x000a0;581)</th><th align="center" valign="top" rowspan="1" colspan="1">Lacosamide 600&#x000a0;mg/day &#x02265;65&#x000a0;years (n&#x000a0;=&#x000a0;91) &#x0003c;65&#x000a0;years (n&#x000a0;=&#x000a0;272)</th><th align="center" valign="top" rowspan="1" colspan="1">Combined 200 and 400&#x000a0;mg/day &#x02265;65&#x000a0;years (n&#x000a0;=&#x000a0;298) &#x0003c;65&#x000a0;years (n&#x000a0;=&#x000a0;732)</th><th align="center" valign="top" rowspan="1" colspan="1">Combined 200, 400, and 600&#x000a0;mg/day &#x02265;65&#x000a0;years (n&#x000a0;=&#x000a0;389) &#x0003c;65&#x000a0;years (n&#x000a0;=&#x000a0;1,004)</th></tr></thead><tbody><tr><td align="left" colspan="7" rowspan="1">Any AE, n (%)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x02265;65&#x000a0;years</td><td align="char" char=" " rowspan="1" colspan="1">74 (65.5)</td><td align="char" char=" " rowspan="1" colspan="1">61 (73.5)</td><td align="char" char=" " rowspan="1" colspan="1">153 (71.2)</td><td align="char" char=" " rowspan="1" colspan="1">76 (83.5)</td><td align="char" char=" " rowspan="1" colspan="1">214 (71.8)</td><td align="char" char=" " rowspan="1" colspan="1">290 (74.6)</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x0003c;65&#x000a0;years</td><td align="char" char=" " rowspan="1" colspan="1">217 (60.8)</td><td align="char" char=" " rowspan="1" colspan="1">122 (80.8)</td><td align="char" char=" " rowspan="1" colspan="1">364 (62.7)</td><td align="char" char=" " rowspan="1" colspan="1">212 (77.9)</td><td align="char" char=" " rowspan="1" colspan="1">486 (66.4)</td><td align="char" char=" " rowspan="1" colspan="1">698 (69.5)</td></tr><tr><td align="left" colspan="7" rowspan="1">Common AEs (in &#x02265;10% of subjects in any lacosamide group), n (%)</td></tr><tr><td align="left" style="padding-left:10%" colspan="7" rowspan="1">Dizziness</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x02265;65&#x000a0;years</td><td align="char" char=" " rowspan="1" colspan="1">5 (4.4)</td><td align="char" char=" " rowspan="1" colspan="1">2 (2.4)</td><td align="char" char=" " rowspan="1" colspan="1">33 (15.3)</td><td align="char" char=" " rowspan="1" colspan="1">28 (30.8)</td><td align="char" char=" " rowspan="1" colspan="1">35 (11.7)</td><td align="char" char=" " rowspan="1" colspan="1">63 (16.2)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x0003c;65&#x000a0;years</td><td align="char" char=" " rowspan="1" colspan="1">13 (3.6)</td><td align="char" char=" " rowspan="1" colspan="1">15 (9.9)</td><td align="char" char=" " rowspan="1" colspan="1">54 (9.3)</td><td align="char" char=" " rowspan="1" colspan="1">64 (23.5)</td><td align="char" char=" " rowspan="1" colspan="1">69 (9.4)</td><td align="char" char=" " rowspan="1" colspan="1">133 (13.2)</td></tr><tr><td align="left" style="padding-left:10%" colspan="7" rowspan="1">Nausea</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x02265;65&#x000a0;years</td><td align="char" char=" " rowspan="1" colspan="1">7 (6.2)</td><td align="char" char=" " rowspan="1" colspan="1">6 (7.2)</td><td align="char" char=" " rowspan="1" colspan="1">21 (9.8)</td><td align="char" char=" " rowspan="1" colspan="1">12 (13.2)</td><td align="char" char=" " rowspan="1" colspan="1">27 (9.1)</td><td align="char" char=" " rowspan="1" colspan="1">39 (10.0)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x0003c;65&#x000a0;years</td><td align="char" char=" " rowspan="1" colspan="1">15 (4.2)</td><td align="char" char=" " rowspan="1" colspan="1">16 (10.6)</td><td align="char" char=" " rowspan="1" colspan="1">36 (6.2)</td><td align="char" char=" " rowspan="1" colspan="1">42 (15.4)</td><td align="char" char=" " rowspan="1" colspan="1">52 (7.1)</td><td align="char" char=" " rowspan="1" colspan="1">94 (9.4)</td></tr><tr><td align="left" style="padding-left:10%" colspan="7" rowspan="1">Headache</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x02265;65&#x000a0;years</td><td align="char" char=" " rowspan="1" colspan="1">7 (6.2)</td><td align="char" char=" " rowspan="1" colspan="1">5 (6.0)</td><td align="char" char=" " rowspan="1" colspan="1">16 (7.4)</td><td align="char" char=" " rowspan="1" colspan="1">10 (11.0)</td><td align="char" char=" " rowspan="1" colspan="1">21 (7.0)</td><td align="char" char=" " rowspan="1" colspan="1">31 (8.0)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x0003c;65&#x000a0;years</td><td align="char" char=" " rowspan="1" colspan="1">27 (7.6)</td><td align="char" char=" " rowspan="1" colspan="1">15 (9.9)</td><td align="char" char=" " rowspan="1" colspan="1">44 (7.6)</td><td align="char" char=" " rowspan="1" colspan="1">28 (10.3)</td><td align="char" char=" " rowspan="1" colspan="1">59 (8.1)</td><td align="char" char=" " rowspan="1" colspan="1">87 (8.7)</td></tr><tr><td align="left" colspan="7" rowspan="1">Specific AEs (defined as relevant for the elderly population), n (%)</td></tr><tr><td align="left" style="padding-left:10%" colspan="7" rowspan="1">Tremor</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x02265;65&#x000a0;years</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">4 (4.8)</td><td align="char" char=" " rowspan="1" colspan="1">18 (8.4)</td><td align="char" char=" " rowspan="1" colspan="1">13 (14.3)</td><td align="char" char=" " rowspan="1" colspan="1">22 (7.4)</td><td align="char" char=" " rowspan="1" colspan="1">35 (9.0)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x0003c;65&#x000a0;years</td><td align="char" char=" " rowspan="1" colspan="1">3 (0.8)</td><td align="char" char=" " rowspan="1" colspan="1">3 (2.0)</td><td align="char" char=" " rowspan="1" colspan="1">16 (2.8)</td><td align="char" char=" " rowspan="1" colspan="1">21 (7.7)</td><td align="char" char=" " rowspan="1" colspan="1">19 (2.6)</td><td align="char" char=" " rowspan="1" colspan="1">40 (4.0)</td></tr><tr><td align="left" style="padding-left:10%" colspan="7" rowspan="1">Cardiac disorders<xref ref-type="fn" rid="epi412079-note-0009">a</xref>
</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x02265;65&#x000a0;years</td><td align="char" char=" " rowspan="1" colspan="1">7 (6.2)</td><td align="char" char=" " rowspan="1" colspan="1">4 (4.8)</td><td align="char" char=" " rowspan="1" colspan="1">15 (7.0)</td><td align="char" char=" " rowspan="1" colspan="1">7 (7.7)</td><td align="char" char=" " rowspan="1" colspan="1">19 (6.4)</td><td align="char" char=" " rowspan="1" colspan="1">26 (6.7)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x0003c;65&#x000a0;years</td><td align="char" char=" " rowspan="1" colspan="1">14 (3.9)</td><td align="char" char=" " rowspan="1" colspan="1">5 (3.3)</td><td align="char" char=" " rowspan="1" colspan="1">24 (4.1)</td><td align="char" char=" " rowspan="1" colspan="1">11 (4.0)</td><td align="char" char=" " rowspan="1" colspan="1">29 (4.0)</td><td align="char" char=" " rowspan="1" colspan="1">40 (4.0)</td></tr><tr><td align="left" style="padding-left:10%" colspan="7" rowspan="1">Balance disorder</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x02265;65&#x000a0;years</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">4 (4.8)</td><td align="char" char=" " rowspan="1" colspan="1">11 (5.1)</td><td align="char" char=" " rowspan="1" colspan="1">11 (12.1)</td><td align="char" char=" " rowspan="1" colspan="1">15 (5.0)</td><td align="char" char=" " rowspan="1" colspan="1">26 (6.7)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x0003c;65&#x000a0;years</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">5 (0.9)</td><td align="char" char=" " rowspan="1" colspan="1">9 (3.3)</td><td align="char" char=" " rowspan="1" colspan="1">5 (0.7)</td><td align="char" char=" " rowspan="1" colspan="1">14 (1.4)</td></tr><tr><td align="left" style="padding-left:10%" colspan="7" rowspan="1">Fall</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x02265;65&#x000a0;years</td><td align="char" char=" " rowspan="1" colspan="1">2 (1.8)</td><td align="char" char=" " rowspan="1" colspan="1">1 (1.2)</td><td align="char" char=" " rowspan="1" colspan="1">3 (1.4)</td><td align="char" char=" " rowspan="1" colspan="1">3 (3.3)</td><td align="char" char=" " rowspan="1" colspan="1">4 (1.3)</td><td align="char" char=" " rowspan="1" colspan="1">7 (1.8)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x0003c;65&#x000a0;years</td><td align="char" char=" " rowspan="1" colspan="1">1 (0.3)</td><td align="char" char=" " rowspan="1" colspan="1">1 (0.7)</td><td align="char" char=" " rowspan="1" colspan="1">5 (0.9)</td><td align="char" char=" " rowspan="1" colspan="1">7 (2.6)</td><td align="char" char=" " rowspan="1" colspan="1">6 (0.8)</td><td align="char" char=" " rowspan="1" colspan="1">13 (1.3)</td></tr><tr><td align="left" style="padding-left:10%" colspan="7" rowspan="1">Gait disturbance</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x02265;65&#x000a0;years</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">3 (1.4)</td><td align="char" char=" " rowspan="1" colspan="1">2 (2.2)</td><td align="char" char=" " rowspan="1" colspan="1">3 (1.0)</td><td align="char" char=" " rowspan="1" colspan="1">5 (1.3)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x0003c;65&#x000a0;years</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">1 (0.2)</td><td align="char" char=" " rowspan="1" colspan="1">5 (1.8)</td><td align="char" char=" " rowspan="1" colspan="1">1 (0.1)</td><td align="char" char=" " rowspan="1" colspan="1">6 (0.6)</td></tr><tr><td align="left" style="padding-left:10%" colspan="7" rowspan="1">Any SAE, n (%)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x02265;65&#x000a0;years</td><td align="char" char=" " rowspan="1" colspan="1">8 (7.1)</td><td align="char" char=" " rowspan="1" colspan="1">3 (3.6)</td><td align="char" char=" " rowspan="1" colspan="1">19 (8.8)</td><td align="char" char=" " rowspan="1" colspan="1">9 (9.9)</td><td align="char" char=" " rowspan="1" colspan="1">22 (7.4)</td><td align="char" char=" " rowspan="1" colspan="1">31 (8.0)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x0003c;65&#x000a0;years</td><td align="char" char=" " rowspan="1" colspan="1">20 (5.6)</td><td align="char" char=" " rowspan="1" colspan="1">7 (4.6)</td><td align="char" char=" " rowspan="1" colspan="1">38 (6.5)</td><td align="char" char=" " rowspan="1" colspan="1">20 (7.4)</td><td align="char" char=" " rowspan="1" colspan="1">45 (6.1)</td><td align="char" char=" " rowspan="1" colspan="1">65 (6.5)</td></tr><tr><td align="left" style="padding-left:10%" colspan="7" rowspan="1">Cardiac SAEs, n (%)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x02265;65&#x000a0;years</td><td align="char" char=" " rowspan="1" colspan="1">3 (2.7)</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">2 (0.9)</td><td align="char" char=" " rowspan="1" colspan="1">2 (2.2)</td><td align="char" char=" " rowspan="1" colspan="1">2 (0.7)</td><td align="char" char=" " rowspan="1" colspan="1">4 (1.0)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x0003c;65&#x000a0;years</td><td align="char" char=" " rowspan="1" colspan="1">3 (0.8)</td><td align="char" char=" " rowspan="1" colspan="1">1 (0.7)</td><td align="char" char=" " rowspan="1" colspan="1">6 (1.0)</td><td align="char" char=" " rowspan="1" colspan="1">4 (1.5)</td><td align="char" char=" " rowspan="1" colspan="1">7 (1.0)</td><td align="char" char=" " rowspan="1" colspan="1">11 (1.1)</td></tr><tr><td align="left" colspan="7" rowspan="1">Discontinuation resulting from:</td></tr><tr><td align="left" style="padding-left:10%" colspan="7" rowspan="1">Any AE, n (%)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x02265;65&#x000a0;years</td><td align="char" char=" " rowspan="1" colspan="1">10 (8.8)</td><td align="char" char=" " rowspan="1" colspan="1">8 (9.6)</td><td align="char" char=" " rowspan="1" colspan="1">54 (25.1)</td><td align="char" char=" " rowspan="1" colspan="1">48 (52.7)</td><td align="char" char=" " rowspan="1" colspan="1">62 (20.8)</td><td align="char" char=" " rowspan="1" colspan="1">110 (28.3)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x0003c;65&#x000a0;years</td><td align="char" char=" " rowspan="1" colspan="1">25 (7.0)</td><td align="char" char=" " rowspan="1" colspan="1">18 (11.9)</td><td align="char" char=" " rowspan="1" colspan="1">63 (10.8)</td><td align="char" char=" " rowspan="1" colspan="1">77 (28.3)</td><td align="char" char=" " rowspan="1" colspan="1">81 (11.1)</td><td align="char" char=" " rowspan="1" colspan="1">158 (15.7)</td></tr><tr><td align="left" style="padding-left:10%" colspan="7" rowspan="1">Dizziness, n (%)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x02265;65&#x000a0;years</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">1 (1.2)</td><td align="char" char=" " rowspan="1" colspan="1">11 (5.1)</td><td align="char" char=" " rowspan="1" colspan="1">11 (12.1)</td><td align="char" char=" " rowspan="1" colspan="1">12 (4.0)</td><td align="char" char=" " rowspan="1" colspan="1">23 (5.9)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x0003c;65&#x000a0;years</td><td align="char" char=" " rowspan="1" colspan="1">0</td><td align="char" char=" " rowspan="1" colspan="1">1 (0.7)</td><td align="char" char=" " rowspan="1" colspan="1">9 (1.5)</td><td align="char" char=" " rowspan="1" colspan="1">23 (8.5)</td><td align="char" char=" " rowspan="1" colspan="1">10 (1.4)</td><td align="char" char=" " rowspan="1" colspan="1">33 (3.3)</td></tr><tr><td align="left" style="padding-left:10%" colspan="7" rowspan="1">All cardiac AEs, n (%)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x02265;65&#x000a0;years</td><td align="char" char=" " rowspan="1" colspan="1">3 (2.7)</td><td align="char" char=" " rowspan="1" colspan="1">2 (2.4)</td><td align="char" char=" " rowspan="1" colspan="1">5 (2.3)</td><td align="char" char=" " rowspan="1" colspan="1">5 (5.5)</td><td align="char" char=" " rowspan="1" colspan="1">7 (2.3)</td><td align="char" char=" " rowspan="1" colspan="1">12 (3.1)</td></tr><tr><td align="left" style="padding-left:15%" rowspan="1" colspan="1">&#x0003c;65&#x000a0;years</td><td align="char" char=" " rowspan="1" colspan="1">7 (2.0)</td><td align="char" char=" " rowspan="1" colspan="1">1 (0.7)</td><td align="char" char=" " rowspan="1" colspan="1">4 (0.7)</td><td align="char" char=" " rowspan="1" colspan="1">4 (1.5)</td><td align="char" char=" " rowspan="1" colspan="1">5 (0.7)</td><td align="char" char=" " rowspan="1" colspan="1">9 (0.9)</td></tr></tbody></table><table-wrap-foot><fn id="epi412079-note-0008"><p>AE, adverse event; SAE, serious adverse event.</p></fn><fn id="epi412079-note-0009"><label>a</label><p>Reported MedDRA terms for cardiac disorders: acute myocardial infarction, angina pectoris, angina unstable, arrhythmia, atrial fibrillation, atrial flutter, atrioventricular block first degree, atrioventricular block second degree, bradyarrhythmia, bradycardia, bundle branch block left, bundle branch block right, cardiac arrest, cardiac failure congestive, coronary artery disease, extrasystoles, myocardial ischemia, nodal rhythm, palpitations, sinus tachycardia, supraventricular tachycardia, tachycardia, ventricular extrasystoles, ventricular fibrillation, ventricular hypertrophy.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>The discontinuation rates resulting from any AE in elderly versus younger subjects were similar for placebo (8.8% vs. 7.0%) and lacosamide 200&#x000a0;mg/day (9.6% vs. 11.9%) and higher for lacosamide 400&#x000a0;mg/day (25.1% vs. 10.8%) and lacosamide 600&#x000a0;mg/day (52.7% vs. 28.3%) (Table&#x000a0;<xref rid="epi412079-tbl-0004" ref-type="table-wrap">4</xref>). Discontinuation rates resulting from dizziness were similar between elderly and younger subjects for the lacosamide 200&#x02010;mg/day group but slightly higher in the elderly for the 400&#x02010; and 600&#x02010;mg/day groups (Table&#x000a0;<xref rid="epi412079-tbl-0004" ref-type="table-wrap">4</xref>). Other AEs contributing to a higher discontinuation rate in the 600&#x02010;mg/day elderly (occurring in &#x02265;3% of the elderly population vs. the younger group) included nausea (8.8% vs. 4.0%), vomiting (5.5% vs. 0.4%), balance disorder (4.4% vs. 1.1%), coordination abnormal (4.4% vs. 0.7%), headache (4.4% vs. 0%), tremor (4.4% vs. 1.5%), and somnolence (3.3% vs. 1.1%). Discontinuations resulting from cardiac AEs were low in both the elderly (2.7%, 2.4%, 2.3%, lacosamide 200, 400, and 600&#x000a0;mg/day, respectively, and 5.5% for placebo) and the younger subjects (2.0%, 0.7%, 0.7%, and 1.5%, respectively). One elderly subject (75&#x000a0;years, lacosamide 200&#x000a0;mg/day) died from a pancreatic carcinoma (causality considered unlikely related). In the younger subject group, one subject (52&#x000a0;years, lacosamide 200&#x000a0;mg/day) committed suicide (causality considered not related) after already being off lacosamide for 72&#x000a0;days; one subject (45&#x000a0;years, lacosamide 400&#x000a0;mg/day) died from worsening coronary artery disease with ventricular fibrillation (causality considered unlikely related), and another subject (48&#x000a0;years, lacosamide 600&#x000a0;mg/day), who had electrocardiogram abnormalities including signs of myocardial infarction at baseline before lacosamide initiation, died from cardiac arrest (causality considered unlikely related).</p><p>In the post hoc multivariate regression analysis, age (&#x0003c;65 vs. &#x02265;65&#x000a0;years) was not a statistically significant factor affecting the incidence of AEs. However, as expected, the higher dose group levels (400 and 600&#x000a0;mg/day) showed a greater increase in the incidence of AEs as compared with the placebo group. In addition, the model showed that females had a higher incidence of AEs as compared with males. Other statistically significant factors that had a very small positive increase on the incidence of AEs included the number of concomitant medications, number of concomitant diseases, and years with diabetic neuropathy (Table&#x000a0;<xref rid="epi412079-tbl-0005" ref-type="table-wrap">5</xref>). From the post hoc Cox proportional hazards model, both age and the number of concomitant diseases were statistically significant factors affecting the rate of discontinuation due to AEs for higher lacosamide dose groups (400 and 600&#x000a0;mg/day), but not for the 200&#x02010;mg/day group. The model showed that older patients (&#x02265;65&#x000a0;years) had a higher risk for discontinuation due to AEs than younger patients (&#x0003c;65&#x000a0;years), and a higher number of diseases was associated with a higher risk for discontinuation due to AEs. Other statistically significant factors included years with diabetic neuropathy (only for the 400&#x02010;mg/day group) and sex (only for the 600&#x02010;mg/day group). A longer duration of diabetic neuropathy was associated with a higher risk for discontinuation due to AEs for the 400&#x02010;mg/day group, and females had a higher risk for discontinuation due to AEs than males for the 600&#x02010;mg/day group (Table&#x000a0;<xref rid="epi412079-tbl-0006" ref-type="table-wrap">6</xref>).</p><table-wrap id="epi412079-tbl-0005" xml:lang="en" orientation="portrait" position="float"><label>Table 5</label><caption><p>Negative binomial model for overall incidence of adverse events in subjects with diabetic neuropathic pain</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Parameter</th><th align="center" valign="top" rowspan="1" colspan="1">Incidence rate ratio (95% CI)</th><th align="center" valign="top" rowspan="1" colspan="1">p Value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">LCM 200&#x000a0;mg/day vs. Placebo</td><td align="char" char=" " rowspan="1" colspan="1">1.085 (0.904,1.302)</td><td align="char" char="." rowspan="1" colspan="1">0.3806</td></tr><tr><td align="left" rowspan="1" colspan="1">LCM 400&#x000a0;mg/day vs. Placebo</td><td align="char" char=" " rowspan="1" colspan="1">1.253 (1.096,1.432)</td><td align="char" char="." rowspan="1" colspan="1">0.0009</td></tr><tr><td align="left" rowspan="1" colspan="1">LCM 600&#x000a0;mg/day vs. Placebo</td><td align="char" char=" " rowspan="1" colspan="1">1.798 (1.540, 2.100)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (&#x02265;65 vs. &#x0003c;65&#x000a0;years)</td><td align="char" char=" " rowspan="1" colspan="1">0.947 (0.841,1.067)</td><td align="char" char="." rowspan="1" colspan="1">0.3716</td></tr><tr><td align="left" rowspan="1" colspan="1">Years with diabetic neuropathy</td><td align="char" char=" " rowspan="1" colspan="1">1.047 (1.020,1.076)</td><td align="char" char="." rowspan="1" colspan="1">0.0007</td></tr><tr><td align="left" rowspan="1" colspan="1">Number of concomitant diseases</td><td align="char" char=" " rowspan="1" colspan="1">1.026 (1.012,1.041)</td><td align="char" char="." rowspan="1" colspan="1">0.0003</td></tr><tr><td align="left" rowspan="1" colspan="1">Number of concomitant medications</td><td align="char" char=" " rowspan="1" colspan="1">1.097 (1.081,1.113)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Sex (female vs. male)</td><td align="char" char=" " rowspan="1" colspan="1">1.203 (1.084,1.334)</td><td align="char" char="." rowspan="1" colspan="1">0.0005</td></tr><tr><td align="left" rowspan="1" colspan="1">Treatment duration (days)</td><td align="char" char=" " rowspan="1" colspan="1">0.999 (0.998,1.000)</td><td align="char" char="." rowspan="1" colspan="1">0.1158</td></tr></tbody></table><table-wrap-foot><fn id="epi412079-note-0010"><p>CI, confidence interval; LCM, lacosamide.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><table-wrap id="epi412079-tbl-0006" xml:lang="en" orientation="portrait" position="float"><label>Table 6</label><caption><p>Cox proportional hazards model for discontinuation due to adverse events by lacosamide treatment group in subjects with diabetic neuropathic pain</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">Hazard ratio (95% CI)</th><th align="center" valign="top" rowspan="1" colspan="1">p Value</th></tr></thead><tbody><tr><td align="left" colspan="3" rowspan="1">Lacosamide 200&#x000a0;mg/day</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Age (&#x02265; 65 vs. &#x0003c;65&#x000a0;years)</td><td align="char" char=" " rowspan="1" colspan="1">0.825 (0.333,1.873)</td><td align="char" char="." rowspan="1" colspan="1">0.6576</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Number of concomitant diseases</td><td align="char" char=" " rowspan="1" colspan="1">1.039 (0.954,1.104)</td><td align="char" char="." rowspan="1" colspan="1">0.2980</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Number of concomitant medications</td><td align="char" char=" " rowspan="1" colspan="1">0.979 (0.890,1.058)</td><td align="char" char="." rowspan="1" colspan="1">0.6334</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Sex (female vs. male)</td><td align="char" char=" " rowspan="1" colspan="1">0.902 (0.396,1.990)</td><td align="char" char="." rowspan="1" colspan="1">0.7994</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Years with diabetic neuropathy</td><td align="char" char=" " rowspan="1" colspan="1">1.016 (0.775,1.320)</td><td align="char" char="." rowspan="1" colspan="1">0.9072</td></tr><tr><td align="left" colspan="3" rowspan="1">Lacosamide 400&#x000a0;mg/day</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Age (&#x02265;65 vs. &#x0003c; 65&#x000a0;years)</td><td align="char" char=" " rowspan="1" colspan="1">2.315 (1.591,3.355)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;.0001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Number of concomitant diseases</td><td align="char" char=" " rowspan="1" colspan="1">1.111 (1.069,1.152)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;.0001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Number of concomitant medications</td><td align="char" char=" " rowspan="1" colspan="1">0.978 (0.929,1.029)</td><td align="char" char="." rowspan="1" colspan="1">0.4044</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Sex (female vs. male)</td><td align="char" char=" " rowspan="1" colspan="1">1.349 (0.938,1.950)</td><td align="char" char="." rowspan="1" colspan="1">0.1077</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Years with diabetic neuropathy</td><td align="char" char=" " rowspan="1" colspan="1">1.077 (0.998,1.149)</td><td align="char" char="." rowspan="1" colspan="1">0.0396</td></tr><tr><td align="left" colspan="3" rowspan="1">Lacosamide 600&#x000a0;mg/day</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Age (&#x02265;65 vs. &#x0003c; 65&#x000a0;years)</td><td align="char" char=" " rowspan="1" colspan="1">2.735 (1.879,3.942)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;.0001</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Number of concomitant diseases</td><td align="char" char=" " rowspan="1" colspan="1">1.047 (1.004,1.090)</td><td align="char" char="." rowspan="1" colspan="1">0.0265</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Number of concomitant medications</td><td align="char" char=" " rowspan="1" colspan="1">1.012 (0.968,1.056)</td><td align="char" char="." rowspan="1" colspan="1">0.5771</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Sex (female vs. male)</td><td align="char" char=" " rowspan="1" colspan="1">1.526 (1.070,2.181)</td><td align="char" char="." rowspan="1" colspan="1">0.0196</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Years with diabetic neuropathy</td><td align="char" char=" " rowspan="1" colspan="1">0.977 (0.885,1.059)</td><td align="char" char="." rowspan="1" colspan="1">0.6115</td></tr></tbody></table><table-wrap-foot><fn id="epi412079-note-0040"><p>CI, confidence interval.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap></sec></sec><sec id="epi412079-sec-0015"><title>Discussion</title><p>Because of low enrollment (1.4%) of elderly subjects in the pivotal clinical trials of adjunctive lacosamide for focal epilepsy, the safety of lacosamide in elderly subjects was examined in the context of DNP studies, which enrolled a more substantial number of elderly subjects. The AE profile in the elderly DNP population was comparable with the known AEs reported from adjunctive lacosamide focal epilepsy trials using similar trial designs and randomized doses.<xref rid="epi412079-bib-0012" ref-type="ref">12</xref> This was true despite the overall older age, higher frequency of concomitant diseases, and higher use of concomitant medications in the DNP population compared with subjects enrolled in epilepsy trials<xref rid="epi412079-bib-0012" ref-type="ref">12</xref> (data on file, UCB Pharma). Dizziness, nausea, and headache were among the most frequently reported AEs in both populations. The incidence of dizziness in the overall lacosamide monotherapy DNP trials was lower than when lacosamide was used as adjunctive AED therapy in focal epilepsy trials (30.6%, combined 200&#x02010;, 400&#x02010;, and 600&#x02010;mg/day doses).<xref rid="epi412079-bib-0012" ref-type="ref">12</xref> This difference is likely attributable to the adjunctive nature of the focal epilepsy trials (with overall 84.4% of subjects taking two or three concomitant AEDs) and potentially additive effects of sodium&#x02010;channel&#x02010;blocking AEDs (taken concomitantly by 82% of the focal epilepsy population<xref rid="epi412079-bib-0023" ref-type="ref">23</xref>). This hypothesis is supported by the similar dizziness rates observed in each of the dose groups of the DNP population as in the subgroup of focal epilepsy subjects adding lacosamide to non&#x02010;sodium&#x02010;channel&#x02010;blocking AEDs.<xref rid="epi412079-bib-0023" ref-type="ref">23</xref>
</p><p>The number of concomitant diseases or their severity may relate to tolerance of perceived AEs. Because treatment of multiple conditions likely requires several medications, these additional drugs may confound the identification of lacosamide&#x02010;related AEs. The same lacosamide&#x02010;related AEs may be more easily identified in subjects with fewer concomitant diseases. The DNP population in this study had a substantial concomitant disease and comedication burden, which is also a common feature of elderly populations. In a study of lamotrigine or sustained&#x02010;release carbamazepine monotherapy in the elderly with newly diagnosed epilepsy, 63% of elderly subjects had cardiovascular disorders, and approximately half had neurological abnormalities; an average of three comedications were taken at screening.<xref rid="epi412079-bib-0024" ref-type="ref">24</xref> Similarly, in a study of controlled&#x02010;release carbamazepine, lamotrigine, or levetiracetam in elderly with new&#x02010;onset focal epilepsy, subjects had a mean of 5.8 concomitant diseases and 5.1 comedications at baseline.<xref rid="epi412079-bib-0025" ref-type="ref">25</xref> A study of adjunctive levetiracetam in elderly with focal epilepsy reported that 83% of subjects had concomitant disease at baseline and 75% received comedications other than AEDs.<xref rid="epi412079-bib-0026" ref-type="ref">26</xref> The most prevalent comorbidities were hypertension (33%), diabetes (12.2%), coronary artery disease (7.5%), and depression (4.5%).<xref rid="epi412079-bib-0026" ref-type="ref">26</xref> Our DNP population had many different comorbidities (mostly related to metabolic, central nervous system, and cardiovascular disorders), which was similar to those reported in elderly focal epilepsy studies.<xref rid="epi412079-bib-0024" ref-type="ref">24</xref>, <xref rid="epi412079-bib-0025" ref-type="ref">25</xref>, <xref rid="epi412079-bib-0026" ref-type="ref">26</xref>
</p><p>A post hoc multivariate regression analysis for the DNP population revealed that the main factors affecting incidence of AEs included higher doses of lacosamide (400 and 600&#x000a0;mg/day) versus placebo, and female versus male sex; age (&#x0003c;65 vs. &#x02265;65&#x000a0;years) was not a significant factor.</p><p>The discontinuation rates resulting from any AE in subjects with DNP receiving 200&#x000a0;mg/day lacosamide were similar between elderly (&#x02265;65&#x000a0;years) and younger (&#x0003c;65&#x000a0;years) subjects. However, at higher doses (400 and 600&#x000a0;mg/day) the discontinuation rates resulting from any AE were higher in the elderly versus the younger subjects. A post hoc Cox proportional hazards regression analysis for each lacosamide dose group showed that age and number of concomitant diseases were statistically significant factors affecting the rate of discontinuation due to AEs for higher dose groups (400 and 600&#x000a0;mg/day), but not for the 200&#x02010;mg/day group. An important limitation to interpreting the safety profile of fixed&#x02010;dose randomized clinical trials is that drug dosing is entirely based on the predetermined randomization schedule independent of the subject's individual tolerability profile. Such forced dosing may lead to higher overall discontinuation rates because of AEs, especially at higher doses. In real&#x02010;life medical practice, most elderly subjects with newly diagnosed epilepsy are expected to require rather low doses of AEDs to maintain seizure control. However, some subjects may still require higher doses to achieve seizure control, and the benefit of higher doses needs to be evaluated as a function of the individual subject's response to efficacy and tolerability. Because higher discontinuation rates would be anticipated in elderly subjects treated with AED polytherapy, studies and guidance have focused on AED monotherapy for elderly subjects newly diagnosed with focal epilepsy.<xref rid="epi412079-bib-0006" ref-type="ref">6</xref> In a study comparing the efficacy of monotherapy AEDs in the elderly with focal epilepsy, discontinuations because of AEs occurred for 32.2% of subjects treated with the continuous&#x02010;release formulation of carbamazepine and 26.3% of lamotrigine&#x02010;treated subjects versus 17.2% of levetiracetam&#x02010;treated subjects.<xref rid="epi412079-bib-0025" ref-type="ref">25</xref> However, it should be noted that once the low target dose was reached for all treatment arms, further dose modifications in that study were performed according to tolerability and seizure control to mimic clinical practice. The finding of similar discontinuation rates between age groups receiving lacosamide 200&#x000a0;mg/day but higher rates in the elderly versus younger subjects receiving 400&#x02010; or 600&#x02010;mg/day doses in our dose&#x02010;randomized studies suggests that a similar flexible and individualized approach should be used in clinical practice when doses higher than 200&#x000a0;mg/day are needed to control seizures.</p><p>Our study has several inherent limitations, most notably underlying disease, comorbid diseases, and concomitant medications acting as confounding factors. In the DNP population, the risk of dementia, stroke, and heart disease is high, and AEs may result from the DNP disease process itself rather than from lacosamide treatment. Thus, discerning the disease state itself from lacosamide AEs should be considered when interpreting results. Fixed&#x02010;drug dose randomization in our trials did not take into account the individual subject's response in contrast to real&#x02010;life medical practice, where dosing decisions are driven by the individual subject's efficacy needs and tolerability when higher doses are needed. Study interpretation is also limited by the indirect comparison, for which only descriptive statistical analyses were performed.</p><p>As the elderly population continues to increase, it is important to maximize safety profiles of AEDs, because epilepsy is the third most common central nervous system disease in the elderly. Older subjects with concomitant disease states, increased comedication burden, and physiologic changes have an increased risk of AEs. Individual trial safety data with the use of lacosamide are limited owing to low elderly enrollment rates. Although lacosamide is not approved for the treatment of DNP, the large number of elderly subjects enrolled in the DNP trials provided an opportunity to assess its tolerability in this age group. Pooled data from DNP trials included safety profiles of 502 subjects who were &#x02265;65&#x000a0;years of age. The most common AEs in the elderly were dizziness, nausea, and headache. No age&#x02010;specific signal was evident when AEs were compared in subjects &#x02265;65&#x000a0;years versus &#x0003c;65&#x000a0;years of age in the DNP trials; however, a dose&#x02010;dependent increase was observed in the higher&#x02010;dose groups.</p><p>Discontinuation rates due to AEs for lacosamide 200&#x000a0;mg/day were similar for the elderly and the younger population. The higher discontinuation rate for the elderly versus the younger subjects receiving lacosamide at higher doses suggests that higher doses of lacosamide as monotherapy in elderly subjects needs to be evaluated based on individual subject efficacy response versus tolerability.</p></sec><sec id="epi412079-sec-0017"><title>Disclosure of Conflicts of Interest</title><p>Jacquelyn Bainbridge has received honoraria for service on advisory boards from Sunovion and UCB Pharma, investigator&#x02010;initiated grant funding from Supernus and UCB Pharma, and grant support from NINDS. Marc De Backer, Klaus Eckhardt, Frank Tennigkeit, Sabine Bongardt, and Konrad J. Werhahn are all employees of UCB Pharma. David Sen was an employee of UCB Pharma at the time of the study. Aziz Shaibani has no conflict of interest to disclose. Edward Faught has received consulting fees from Eisai, SAGE, Sunovion, UCB, and Upsher&#x02010;Smith and for service on Data Safety Monitoring Boards from Eisai, Lundbeck, and SK Life Science. Edward Faught has received research support from Brain Sentinel and UCB. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guideline.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="epi412079-sup-0001"><caption><p>
<bold>Table&#x000a0;S1</bold>. Specific cardiac AEs recorded during the treatment phase (i.e., titration and maintenance phase) with lacosamide monotherapy in subjects with diabetic neuropathic pain, presented by age (&#x0003c;65&#x000a0;years or &#x02265;65&#x000a0;years).</p></caption><media xlink:href="EPI4-2-415-s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="epi412079-sec-0016"><title>Acknowledgments</title><p>This study was a UCB Pharma&#x02013;sponsored study. The authors acknowledge the contributions of David Rudd to this analysis. The authors thank the subjects and their caregivers in addition to the investigators and their teams who contributed to this study. The authors acknowledge Jesse Fishman, PharmD, of UCB Pharma (Atlanta, Georgia, U.S.A.) for publication coordination. Editorial support was provided by Richard Fay and Lynne Isbell of Evidence Scientific Solutions (Philadelphia, Pennsylvania, U.S.A.) and was funded by UCB Pharma.</p></ack><bio id="epi412079-biog-0001"><p>
<bold>Jacquelyn L. Bainbridge</bold>, PharmD, is Professor of Clinical Pharmacy at the Skaggs School of Pharmacy and Pharmaceutical Sciences on the Anschutz Medical Campus, University of Colorado.</p><graphic xlink:href="EPI4-2-415-g001.gif" position="anchor" id="nlm-graphic-1" orientation="portrait"/></bio><ref-list content-type="cited-references" id="epi412079-bibl-0001"><title>References</title><ref id="epi412079-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="epi412079-cit-0001">
<string-name>
<surname>Hauser</surname>
<given-names>WA</given-names>
</string-name>, <string-name>
<surname>Annegers</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Kurland</surname>
<given-names>LT</given-names>
</string-name>. <article-title>Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935&#x02013;1984</article-title>. <source>Epilepsia</source>
<year>1993</year>;<volume>34</volume>:<fpage>453</fpage>&#x02013;<lpage>468</lpage>.<pub-id pub-id-type="pmid">8504780</pub-id></mixed-citation></ref><ref id="epi412079-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="epi412079-cit-0002">
<string-name>
<surname>Leppik</surname>
<given-names>IE</given-names>
</string-name>, <string-name>
<surname>Walczak</surname>
<given-names>TS</given-names>
</string-name>, <string-name>
<surname>Birnbaum</surname>
<given-names>AK</given-names>
</string-name>. <article-title>Challenges of epilepsy in elderly people</article-title>. <source>Lancet</source>
<year>2012</year>;<volume>380</volume>:<fpage>1128</fpage>&#x02013;<lpage>1130</lpage>.<pub-id pub-id-type="pmid">23021270</pub-id></mixed-citation></ref><ref id="epi412079-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="epi412079-cit-0003">
<string-name>
<surname>Stefan</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>May</surname>
<given-names>TW</given-names>
</string-name>, <string-name>
<surname>Pf&#x000e4;fflin</surname>
<given-names>M</given-names>
</string-name>, et&#x000a0;al. <article-title>Epilepsy in the elderly: comparing clinical characteristics with younger patients</article-title>. <source>Acta Neurol Scand</source>
<year>2014</year>;<volume>129</volume>:<fpage>283</fpage>&#x02013;<lpage>293</lpage>.<pub-id pub-id-type="pmid">24495079</pub-id></mixed-citation></ref><ref id="epi412079-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="epi412079-cit-0004">
<string-name>
<surname>Faught</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Richman</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Martin</surname>
<given-names>R</given-names>
</string-name>, et&#x000a0;al. <article-title>Incidence and prevalence of epilepsy among older U.S. Medicare beneficiaries</article-title>. <source>Neurology</source>
<year>2012</year>;<volume>78</volume>:<fpage>448</fpage>&#x02013;<lpage>453</lpage>.<pub-id pub-id-type="pmid">22262750</pub-id></mixed-citation></ref><ref id="epi412079-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="epi412079-cit-0005">
<string-name>
<surname>Pugh</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Knoefel</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Mortensen</surname>
<given-names>EM</given-names>
</string-name>, et&#x000a0;al. <article-title>New&#x02010;onset epilepsy risk factors in older veterans</article-title>. <source>J Am Geriatr Soc</source>
<year>2009</year>;<volume>57</volume>:<fpage>237</fpage>&#x02013;<lpage>242</lpage>.<pub-id pub-id-type="pmid">19207140</pub-id></mixed-citation></ref><ref id="epi412079-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="epi412079-cit-0006">
<string-name>
<surname>Stefan</surname>
<given-names>H</given-names>
</string-name>. <article-title>Epilepsy in the elderly: facts and challenges</article-title>. <source>Acta Neurol Scand</source>
<year>2011</year>;<volume>124</volume>:<fpage>223</fpage>&#x02013;<lpage>237</lpage>.<pub-id pub-id-type="pmid">21143593</pub-id></mixed-citation></ref><ref id="epi412079-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="epi412079-cit-0007">
<string-name>
<surname>Gidal</surname>
<given-names>BE</given-names>
</string-name>, <string-name>
<surname>French</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Grossman</surname>
<given-names>P</given-names>
</string-name>, et&#x000a0;al. <article-title>Assessment of potential drug interactions in patients with epilepsy: impact of age and sex</article-title>. <source>Neurology</source>
<year>2009</year>;<volume>72</volume>:<fpage>419</fpage>&#x02013;<lpage>425</lpage>.<pub-id pub-id-type="pmid">19188572</pub-id></mixed-citation></ref><ref id="epi412079-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="epi412079-cit-0008">
<string-name>
<surname>Brodie</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Elder</surname>
<given-names>AT</given-names>
</string-name>, <string-name>
<surname>Kwan</surname>
<given-names>P</given-names>
</string-name>. <article-title>Epilepsy in later life</article-title>. <source>Lancet Neurol</source>
<year>2009</year>;<volume>8</volume>:<fpage>1019</fpage>&#x02013;<lpage>1030</lpage>.<pub-id pub-id-type="pmid">19800848</pub-id></mixed-citation></ref><ref id="epi412079-bib-0009"><label>9</label><mixed-citation publication-type="miscellaneous" id="epi412079-cit-0009">
<collab collab-type="authors">UCB Pharma</collab>
. <article-title>Vimpat<sup>&#x000ae;</sup> (lacosamide tablets, injection, oral solution) U.S. prescribing information</article-title>. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.vimpat.com/pdf/vimpat_PI.pdf">http://www.vimpat.com/pdf/vimpat_PI.pdf</ext-link>. Accessed May 18, 2017.</mixed-citation></ref><ref id="epi412079-bib-0010"><label>10</label><mixed-citation publication-type="miscellaneous" id="epi412079-cit-0010">
<collab collab-type="authors">UCB Pharma</collab>
. <article-title>Vimpat<sup>&#x000ae;</sup> (lacosamide) EMA summary of product characteristics</article-title>. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000863/WC500050338.pdf">http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000863/WC500050338.pdf</ext-link>. Accessed May 18, 2017.</mixed-citation></ref><ref id="epi412079-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="epi412079-cit-0011">
<string-name>
<surname>Cawello</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Stockis</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Andreas</surname>
<given-names>JO</given-names>
</string-name>, et&#x000a0;al. <article-title>Advances in epilepsy treatment: lacosamide pharmacokinetic profile</article-title>. <source>Ann NY Acad Sci</source>
<year>2014</year>;<volume>1329</volume>:<fpage>18</fpage>&#x02013;<lpage>32</lpage>.<pub-id pub-id-type="pmid">25167889</pub-id></mixed-citation></ref><ref id="epi412079-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="epi412079-cit-0012">
<string-name>
<surname>Biton</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Gil&#x02010;Nagel</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Isojarvi</surname>
<given-names>J</given-names>
</string-name>, et&#x000a0;al. <article-title>Safety and tolerability of lacosamide as adjunctive therapy for adults with partial&#x02010;onset seizures: analysis of data pooled from three randomized, double&#x02010;blind, placebo&#x02010;controlled clinical trials</article-title>. <source>Epilepsy Behav</source>
<year>2015</year>;<volume>52</volume>:<fpage>119</fpage>&#x02013;<lpage>127</lpage>.<pub-id pub-id-type="pmid">26414341</pub-id></mixed-citation></ref><ref id="epi412079-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="epi412079-cit-0013">
<string-name>
<surname>Rudd</surname>
<given-names>GD</given-names>
</string-name>, <string-name>
<surname>Haverkamp</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Mason</surname>
<given-names>JW</given-names>
</string-name>, et&#x000a0;al. <article-title>Lacosamide cardiac safety: clinical trials in patients with partial&#x02010;onset seizures</article-title>. <source>Acta Neurol Scand</source>
<year>2015</year>;<volume>132</volume>:<fpage>355</fpage>&#x02013;<lpage>363</lpage>.<pub-id pub-id-type="pmid">25933358</pub-id></mixed-citation></ref><ref id="epi412079-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="epi412079-cit-0014">
<string-name>
<surname>Ben&#x02010;Menachem</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Biton</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Jatuzis</surname>
<given-names>D</given-names>
</string-name>, et&#x000a0;al. <article-title>Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial&#x02010;onset seizures</article-title>. <source>Epilepsia</source>
<year>2007</year>;<volume>48</volume>:<fpage>1308</fpage>&#x02013;<lpage>1317</lpage>.<pub-id pub-id-type="pmid">17635557</pub-id></mixed-citation></ref><ref id="epi412079-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="epi412079-cit-0015">
<string-name>
<surname>Chung</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Sperling</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Biton</surname>
<given-names>V</given-names>
</string-name>, et&#x000a0;al. <article-title>Lacosamide as adjunctive therapy for partial&#x02010;onset seizures: a randomized controlled trial</article-title>. <source>Epilepsia</source>
<year>2010</year>;<volume>51</volume>:<fpage>958</fpage>&#x02013;<lpage>967</lpage>.<pub-id pub-id-type="pmid">20132285</pub-id></mixed-citation></ref><ref id="epi412079-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="epi412079-cit-0016">
<string-name>
<surname>Hal&#x000e1;sz</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>K&#x000e4;lvi&#x000e4;inen</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Mazurkiewicz&#x02010;Beldzi&#x00144;ska</surname>
<given-names>M</given-names>
</string-name>, et&#x000a0;al. <article-title>Adjunctive lacosamide for partial&#x02010;onset seizures: efficacy and safety results from a randomized controlled trial</article-title>. <source>Epilepsia</source>
<year>2009</year>;<volume>50</volume>:<fpage>443</fpage>&#x02013;<lpage>453</lpage>.<pub-id pub-id-type="pmid">19183227</pub-id></mixed-citation></ref><ref id="epi412079-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="epi412079-cit-0017">
<string-name>
<surname>Baulac</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Rosenow</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Toledo</surname>
<given-names>M</given-names>
</string-name>, et&#x000a0;al. <article-title>Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled&#x02010;release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double&#x02010;blind, non&#x02010;inferiority trial</article-title>. <source>Lancet Neurol</source>
<year>2017</year>;<volume>16</volume>:<fpage>43</fpage>&#x02013;<lpage>54</lpage>.<pub-id pub-id-type="pmid">27889312</pub-id></mixed-citation></ref><ref id="epi412079-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="epi412079-cit-0018">
<string-name>
<surname>Rauck</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Shaibani</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Biton</surname>
<given-names>V</given-names>
</string-name>, et&#x000a0;al. <article-title>Lacosamide in painful diabetic peripheral neuropathy: a phase 2 double&#x02010;blind placebo&#x02010;controlled study</article-title>. <source>Clin J Pain</source>
<year>2007</year>;<volume>23</volume>:<fpage>150</fpage>&#x02013;<lpage>158</lpage>.<pub-id pub-id-type="pmid">17237664</pub-id></mixed-citation></ref><ref id="epi412079-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="epi412079-cit-0019">
<string-name>
<surname>Wymer</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Simpson</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Sen</surname>
<given-names>D</given-names>
</string-name>, et&#x000a0;al. <article-title>Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18&#x02010;week double&#x02010;blind placebo&#x02010;controlled trial of fixed&#x02010;dose regimens</article-title>. <source>Clin J Pain</source>
<year>2009</year>;<volume>25</volume>:<fpage>376</fpage>&#x02013;<lpage>385</lpage>.<pub-id pub-id-type="pmid">19454870</pub-id></mixed-citation></ref><ref id="epi412079-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="epi412079-cit-0020">
<string-name>
<surname>Ziegler</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Hidv&#x000e9;gi</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Gurieva</surname>
<given-names>I</given-names>
</string-name>, et&#x000a0;al. <article-title>Efficacy and safety of lacosamide in painful diabetic neuropathy</article-title>. <source>Diabetes Care</source>
<year>2010</year>;<volume>33</volume>:<fpage>839</fpage>&#x02013;<lpage>841</lpage>.<pub-id pub-id-type="pmid">20067958</pub-id></mixed-citation></ref><ref id="epi412079-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="epi412079-cit-0021">
<string-name>
<surname>Shaibani</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Fares</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Selam</surname>
<given-names>JL</given-names>
</string-name>, et&#x000a0;al. <article-title>Lacosamide in painful diabetic neuropathy: an 18&#x02010;week double&#x02010;blind placebo&#x02010;controlled trial</article-title>. <source>J Pain</source>
<year>2009</year>;<volume>10</volume>:<fpage>818</fpage>&#x02013;<lpage>828</lpage>.<pub-id pub-id-type="pmid">19409861</pub-id></mixed-citation></ref><ref id="epi412079-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="epi412079-cit-0022">
<string-name>
<surname>Bongardt</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Bain</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Tzschaschel</surname>
<given-names>B</given-names>
</string-name>, et&#x000a0;al. <article-title>Lacosamide reduces pain in subjects with diabetic neuropathic pain</article-title>. <source>Ann Neurol</source>
<year>2008</year>;<volume>64</volume>:<fpage>S25</fpage>.</mixed-citation></ref><ref id="epi412079-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="epi412079-cit-0023">
<string-name>
<surname>Sake</surname>
<given-names>JK</given-names>
</string-name>, <string-name>
<surname>Hebert</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Isoj&#x000e4;rvi</surname>
<given-names>J</given-names>
</string-name>, et&#x000a0;al. <article-title>A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs</article-title>. <source>CNS Drugs</source>
<year>2010</year>;<volume>24</volume>:<fpage>1055</fpage>&#x02013;<lpage>1068</lpage>.<pub-id pub-id-type="pmid">21090839</pub-id></mixed-citation></ref><ref id="epi412079-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="epi412079-cit-0024">
<string-name>
<surname>Saetre</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Perucca</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Isoj&#x000e4;rvi</surname>
<given-names>J</given-names>
</string-name>, et&#x000a0;al. <article-title>An international multicenter randomized double&#x02010;blind controlled trial of lamotrigine and sustained&#x02010;release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly</article-title>. <source>Epilepsia</source>
<year>2007</year>;<volume>48</volume>:<fpage>1292</fpage>&#x02013;<lpage>1302</lpage>.<pub-id pub-id-type="pmid">17561956</pub-id></mixed-citation></ref><ref id="epi412079-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="epi412079-cit-0025">
<string-name>
<surname>Werhahn</surname>
<given-names>KJ</given-names>
</string-name>, <string-name>
<surname>Trinka</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Dobesberger</surname>
<given-names>J</given-names>
</string-name>, et&#x000a0;al. <article-title>A randomized, double&#x02010;blind comparison of antiepileptic drug treatment in the elderly with new&#x02010;onset focal epilepsy</article-title>. <source>Epilepsia</source>
<year>2015</year>;<volume>56</volume>:<fpage>450</fpage>&#x02013;<lpage>459</lpage>.<pub-id pub-id-type="pmid">25684224</pub-id></mixed-citation></ref><ref id="epi412079-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="epi412079-cit-0026">
<string-name>
<surname>Werhahn</surname>
<given-names>KJ</given-names>
</string-name>, <string-name>
<surname>Klimpe</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Balkaya</surname>
<given-names>S</given-names>
</string-name>, et&#x000a0;al. <article-title>The safety and efficacy of add&#x02010;on levetiracetam in elderly patients with focal epilepsy: a one&#x02010;year observational study</article-title>. <source>Seizure</source>
<year>2011</year>;<volume>20</volume>:<fpage>305</fpage>&#x02013;<lpage>311</lpage>.<pub-id pub-id-type="pmid">21257324</pub-id></mixed-citation></ref></ref-list></back></article>